top of page
Home
About
Company Overview
Our Team
Technology
Masked ImmunoCytokines
Nammisomes
Products
QXL138AM
SLNP-IC1
NTI-121
Pipeline
News
Contact
More
Use tab to navigate through the menu items.
News
Nammi Therapeutics, Inc. Announces First Patient Dosed with QXL138AM in a Phase 1 Study Evaluating Advanced Solid Tumors and Multiple Myeloma
Nammi Therapeutics Completes Series B Round with Investment from MMRF's Myeloma Investment Fund
Nammi Therapeutics Featured in Los Angeles Business Journal
Publications and Presentations
bottom of page
